Abstract

Introduction Parkinson's disease (PD) is characterized by a triad of motor symptoms and several nonmotor symptoms (NMS). Identifying the most appropriate treatment is essential for improving patient quality of life (QoL). However, it is still not known which PD symptoms more commonly affect patients with advanced PD (APD) versus non-APD. This study examined the factors that most affected the QoL of patients with APD (defined using the 5-2-1 criteria: ≥5 oral levodopa doses a day, off time ≥2 hours a day, or troublesome dyskinesia ≥1 hour a day) versus non-APD in a large Japanese population using the Japanese Quality-of-Life Survey of Parkinson's Disease (JAQPAD) study. Methods Participants in this self-reported survey-based study included all members of the Japan Parkinson's Disease Association. Questionnaires assessing NMS and QoL (e.g., the 8-item PD Questionnaire [PDQ-8]) were included. Univariate and multivariate regression analyses were conducted to identify clinical factors impacting QoL using the PDQ-8 Summary Index (PDQ-8 SI). Results Of the 3022 eligible patients, 864 were classified as having non-APD and 1599 as having APD. QoL as assessed by the PDQ-8 SI was notably worse in patients with APD versus non-APD (39.2 vs. 26.9, p < 0.0001). Although off time affected QoL only in patients with APD, PD duration and the NMS Questionnaire score significantly contributed to the QoL in both patients with APD and non-APD. Conclusions This study identified the factors more commonly associated with worse QoL in patients with APD versus non-APD. Our findings offer new insights for providing optimal treatment and improving treatment satisfaction in patients with PD.

Highlights

  • Parkinson’s disease (PD) is characterized by a triad of motor symptoms and several nonmotor symptoms (NMS)

  • The average age at PD diagnosis was higher in the non-advanced PD (APD) group than in the APD group (63.6 vs. 58.6 years), and the mean duration of PD was greater in patients with APD (7.6 vs. 11.9 years)

  • A majority of the patients in both groups were in Hoehn and Yahr (H&Y) stage 3, and there was a statistically significant difference between the H&Y stages in the non-APD and APD groups (p < 0.0001)

Read more

Summary

Introduction

Parkinson’s disease (PD) is characterized by a triad of motor symptoms and several nonmotor symptoms (NMS). Identifying the most appropriate treatment is essential for improving patient quality of life (QoL) It is still not known which PD symptoms more commonly affect patients with advanced PD (APD) versus non-APD. Is study examined the factors that most affected the QoL of patients with APD (defined using the 5-2-1 criteria: ≥5 oral levodopa doses a day, off time ≥2 hours a day, or troublesome dyskinesia ≥1 hour a day) versus non-APD in a large Japanese population using the Japanese Quality-of-Life Survey of Parkinson’s Disease (JAQPAD) study. E median rating for these patients on the Hoehn and Yahr (H&Y) scale was stage 3, with 75% reporting motor fluctuations; these patients had only mild cognitive impairment, and a majority (89%) continued to reside at home [13] Such findings highlight the complexity of defining APD and suggest that the concept of APD may need to be individualized

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call